Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 12 | 2024 | 236 | 0.930 |
Why?
|
| Aging | 11 | 2019 | 190 | 0.900 |
Why?
|
| Brain | 9 | 2024 | 197 | 0.870 |
Why?
|
| Cognitive Dysfunction | 10 | 2019 | 149 | 0.860 |
Why?
|
| Cognition | 11 | 2024 | 203 | 0.760 |
Why?
|
| Aged, 80 and over | 24 | 2024 | 540 | 0.680 |
Why?
|
| Aged | 25 | 2024 | 898 | 0.660 |
Why?
|
| Female | 30 | 2024 | 1644 | 0.640 |
Why?
|
| Male | 30 | 2024 | 1781 | 0.640 |
Why?
|
| Cognition Disorders | 7 | 2018 | 163 | 0.590 |
Why?
|
| Humans | 31 | 2024 | 2822 | 0.540 |
Why?
|
| Longitudinal Studies | 12 | 2019 | 246 | 0.450 |
Why?
|
| Neuropsychological Tests | 12 | 2019 | 223 | 0.400 |
Why?
|
| Parkinsonian Disorders | 3 | 2017 | 24 | 0.380 |
Why?
|
| Cohort Studies | 10 | 2024 | 222 | 0.310 |
Why?
|
| Neuropathology | 3 | 2018 | 15 | 0.300 |
Why?
|
| Cognitive Aging | 2 | 2018 | 24 | 0.270 |
Why?
|
| Dementia | 2 | 2018 | 68 | 0.270 |
Why?
|
| Parkinson Disease | 3 | 2017 | 65 | 0.260 |
Why?
|
| Neurodegenerative Diseases | 2 | 2018 | 32 | 0.250 |
Why?
|
| HIV Infections | 2 | 2017 | 95 | 0.240 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 2015 | 17 | 0.240 |
Why?
|
| DNA-Binding Proteins | 4 | 2019 | 68 | 0.220 |
Why?
|
| Memory, Short-Term | 3 | 2019 | 23 | 0.210 |
Why?
|
| Independent Living | 3 | 2018 | 28 | 0.210 |
Why?
|
| Perception | 2 | 2019 | 20 | 0.190 |
Why?
|
| Memory, Episodic | 2 | 2019 | 21 | 0.180 |
Why?
|
| Loneliness | 2 | 2017 | 17 | 0.160 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 9 | 0.160 |
Why?
|
| Risk Factors | 6 | 2017 | 263 | 0.160 |
Why?
|
| Hippocampus | 2 | 2019 | 41 | 0.150 |
Why?
|
| Hypoventilation | 2 | 2010 | 25 | 0.150 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2018 | 4 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 16 | 0.150 |
Why?
|
| Osteoporosis | 1 | 2018 | 23 | 0.150 |
Why?
|
| Cholecystokinin | 2 | 2011 | 5 | 0.140 |
Why?
|
| Hallucinations | 2 | 2011 | 7 | 0.140 |
Why?
|
| Brain Infarction | 1 | 2018 | 20 | 0.140 |
Why?
|
| Learning | 1 | 2018 | 20 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 9 | 0.140 |
Why?
|
| Memory Disorders | 1 | 2018 | 28 | 0.140 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 6 | 0.140 |
Why?
|
| Literacy | 1 | 2017 | 4 | 0.140 |
Why?
|
| Disease Progression | 4 | 2019 | 95 | 0.130 |
Why?
|
| Apolipoprotein E4 | 2 | 2015 | 72 | 0.130 |
Why?
|
| Biostatistics | 1 | 2016 | 3 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2016 | 27 | 0.120 |
Why?
|
| Plaque, Amyloid | 1 | 2015 | 19 | 0.120 |
Why?
|
| Motor Disorders | 1 | 2015 | 3 | 0.120 |
Why?
|
| Middle Aged | 5 | 2017 | 756 | 0.120 |
Why?
|
| Motor Activity | 1 | 2015 | 51 | 0.110 |
Why?
|
| Antiporters | 1 | 2015 | 4 | 0.110 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 4 | 0.110 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 4 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 5 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 6 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 11 | 0.110 |
Why?
|
| Interpersonal Relations | 1 | 2014 | 10 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 23 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 97 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2015 | 19 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2015 | 44 | 0.110 |
Why?
|
| Autopsy | 3 | 2019 | 39 | 0.110 |
Why?
|
| Comorbidity | 3 | 2018 | 48 | 0.110 |
Why?
|
| Incidence | 3 | 2018 | 105 | 0.100 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 33 | 0.090 |
Why?
|
| Abnormalities, Multiple | 2 | 2010 | 5 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2010 | 16 | 0.090 |
Why?
|
| Homeodomain Proteins | 2 | 2010 | 35 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2010 | 47 | 0.090 |
Why?
|
| Amyloid beta-Peptides | 2 | 2024 | 27 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 42 | 0.090 |
Why?
|
| Substantia Innominata | 1 | 2009 | 3 | 0.080 |
Why?
|
| Amnesia | 1 | 2009 | 7 | 0.080 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 23 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 77 | 0.080 |
Why?
|
| Lewy Bodies | 2 | 2019 | 37 | 0.070 |
Why?
|
| Death, Sudden | 1 | 2008 | 3 | 0.070 |
Why?
|
| Sclerosis | 2 | 2019 | 25 | 0.070 |
Why?
|
| Dioxoles | 1 | 2006 | 3 | 0.060 |
Why?
|
| Receptors, AMPA | 1 | 2006 | 5 | 0.060 |
Why?
|
| Piperidines | 1 | 2006 | 7 | 0.060 |
Why?
|
| Child Behavior Disorders | 1 | 2006 | 6 | 0.060 |
Why?
|
| Lewy Body Disease | 2 | 2018 | 13 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 100 | 0.060 |
Why?
|
| Illinois | 2 | 2017 | 21 | 0.060 |
Why?
|
| United States | 2 | 2017 | 231 | 0.060 |
Why?
|
| Logistic Models | 2 | 2016 | 59 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 139 | 0.060 |
Why?
|
| Fragile X Syndrome | 1 | 2006 | 108 | 0.060 |
Why?
|
| Risk | 2 | 2015 | 43 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 20 | 0.060 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 12 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2017 | 18 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 46 | 0.050 |
Why?
|
| Genotype | 2 | 2015 | 81 | 0.050 |
Why?
|
| Chicago | 2 | 2017 | 148 | 0.050 |
Why?
|
| Adolescent | 3 | 2010 | 241 | 0.050 |
Why?
|
| Adult | 3 | 2010 | 759 | 0.040 |
Why?
|
| Alleles | 2 | 2015 | 62 | 0.040 |
Why?
|
| Syndrome | 2 | 2010 | 21 | 0.040 |
Why?
|
| Prognosis | 1 | 2018 | 39 | 0.040 |
Why?
|
| Prevalence | 1 | 2018 | 39 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 48 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 19 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 49 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 83 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2011 | 15 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2018 | 4 | 0.040 |
Why?
|
| Child | 2 | 2010 | 190 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2011 | 61 | 0.040 |
Why?
|
| Mental Status Schedule | 1 | 2018 | 25 | 0.040 |
Why?
|
| Memory | 1 | 2018 | 43 | 0.040 |
Why?
|
| Biomarkers | 1 | 2018 | 91 | 0.040 |
Why?
|
| Dementia, Vascular | 1 | 2018 | 6 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 1 | 2017 | 25 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 50 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 138 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 10 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 11 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 34 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 37 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 64 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 197 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 20 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 13 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 84 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2015 | 29 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 38 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 7 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 47 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2015 | 17 | 0.030 |
Why?
|
| CpG Islands | 1 | 2015 | 8 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 5 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2015 | 16 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 9 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 13 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2014 | 23 | 0.030 |
Why?
|
| Time Factors | 1 | 2015 | 205 | 0.030 |
Why?
|
| Depression | 1 | 2014 | 57 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2010 | 6 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 30 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 26 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 24 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2009 | 23 | 0.020 |
Why?
|
| Child Development | 1 | 2010 | 13 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 33 | 0.020 |
Why?
|
| Young Adult | 1 | 2010 | 179 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2008 | 2 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 20 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2008 | 118 | 0.020 |
Why?
|
| Mutation | 1 | 2008 | 76 | 0.020 |
Why?
|
| Infant | 1 | 2008 | 122 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2006 | 3 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2006 | 3 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2006 | 5 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 7 | 0.020 |
Why?
|
| Autistic Disorder | 1 | 2006 | 7 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2006 | 10 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 82 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2006 | 182 | 0.020 |
Why?
|
| Dopamine Agents | 1 | 2004 | 3 | 0.010 |
Why?
|